Divarasib (GDC-6036) is a potent, selective, and oral KRAS G12C inhibitor with sub-nanomolar IC50, which irreversibly traps the oncoprotein in an inactive state to suppress tumor growth. It is actively researched in vitro and in vivo for treating solid tumors such as non-small cell lung cancer and colorectal cancer.